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Abstract: The combination of programmed cell death 1/programmed cell death
ligand 1 blockade and thoracic radiotherapy has become the new standard of care in
the treatment of locally advanced non-small-cell lung cancer. The information
regarding the pulmonary safety of such therapy remains limited to mostly
retrospective studies and case reports with a small portion of data from prospective
clinical trials. By analyzing the underlying mechanisms of interactions between
radiation and immunotherapy from preclinical data and summarizing safety data from
relevant clinical studies with pulmonary toxicity, we believe that longer and rigorous
follow-up is warranted, to determine if the combination of such modalities is
appropriate for patients without risking undue toxicity.
Key words: thoracic radiotherapy; immunotherapy; non–small cell lung cancer;
programmed cell death 1/programmed cell death ligand 1; pneumonitis

Introduction
Programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1)
immune checkpoint inhibitors (ICIs) are currently one of the most investigated
immunotherapies. This blockade has proven its efficacy across various types of tumor
including melanoma, Hodgkin`s lymphoma, head and neck cancer, and non-small-cell
lung cancer (NSCLC)1,2. Objective tumor responses are observed in approximately
40% of PD-L1-positive advanced NSCLC patients, accompanied by significantly
increased progression-free survival (PFS) and overall survival (OS) 3-6. This clinical
effect is derived from anti-PD-1/PD-L1 therapy enhancing the antitumor immune
response7. Radiotherapy facilitates the initial antigen-specific immune responses by
inducing inflammatory death of tumor cells, whereby fragmented tumor cells release
previously obscured tumor-associated antigens and immune-stimulatory molecules
which then trigger an immunogenic response which may elicit an in-situ tumor
vaccination effect and abscopal effect8.
Combining radiotherapy with immunotherapy has increasingly become of interest.
Multiple preclinical studies demonstrated that thoracic radiotherapy (TRT) can
augment the efficacy of anti-PD-1/PD-L1 therapy by priming and recruiting more
antitumor effector T cells9-11. Recent clinical trials for anti-PD-1/PD-L1 therapy have
explored the combination of anti-PD-1/PD-L1 therapy with various cancer
therapeutics, including radiotherapy. The combination of anti-PD-1/PD-L1 therapy
with TRT in treating locally advanced or metastatic NSCLC has significantly
improved PFS and OS when compared with monotherapy, which is demonstrated by
the KEYNOTE-001 trial (NCT01295827) (median PFS: 6.3 months vs. 2.0 months;
median OS: 11.6 months vs. 5.3 months) and the PACIFIC study (NCT02125461)
(median PFS: 16.8 months vs. 5.6 months; median OS: not reached vs. 28.7
months)12-14. However, with this increased efficacy may come potential increases in
toxicity15,16. In this review, we will explore the potential toxicity and the underlying
mechanisms. Considering the underlying interactions between the two modalities with
the currently available evidence, we acknowledge and appreciate the significant
efficacy and tremendous promise of the combination of TRT and anti-PD-1/PD-L1
therapy, but have reservations about the view claiming no undue toxicity of this
combination therapy17.
Pulmonary toxicity in anti-PD-1/PD-L1 therapy
Anti-PD-1/PD-L1 monoclonal antibodies (mAbs), is capable of effectively
interdicting the immune inhibitory signals mediated by the interaction between PD-1
and PD-L1, which recovers the priming of tumor-antigen-specific T cells and baseline
immune response against tumor7 (Figure 1A).

Figure 1. The schematic diagram of combination therapy-induced pulmonary toxicity. (A) PD-1/PD-L1
axis inhibitors are capable of effectively recovering the baseline T-cell immune response against tumor.
Inflammatory factors secreted by activated T cells are able to recruit more immunocytes that amplify
the anti-tumor effects as well as the pulmonary toxicity. (B) Thoracic radiotherapy generates DNA
damage to lung tissue, which contributes to the release of cytokines and chemokines that recruit and
activate immunocytes and myo-fibroblasts. (C) The combination of radiotherapy and anti-PD-1/PD-L1
monoclonal antibodies (mAbs) could incur more serious adverse effects relevant to DNA damage,
redundant immunocytes infiltrating and inflammatory factors releasing, and collagen deposition.

Unfortunately, PD-1/PD-L1 blockade can cause collateral damage to normal organs
and tissues, termed immune-related adverse events (irAEs)18, i.e. toxicity mediated by
antibodies, T cells, and cytokines attacking self-antigens. Anti-PD-1/PD-L1
therapy-related pneumonitis, defined as the inflammation of lung parenchyma, is an
indicator of potentially life-threatening irAEs and appears to occur more commonly in
patients with lung cancer19, having resulted in pneumonitis-related deaths observed in
several clinical trials18,20. Paradoxically, NSCLC patients who received nivolumab
and developed irAEs had better OS and longer PFS as compared to those without
irAE21. The pneumonitis has been reported to occur in 0-10% of the patients receiving
anti-PD-1/PD-L1 monotherapy or combination therapy. Delaunay et al. unveiled the
outcomes of a large-scale retrospective study wherein 1826 cancer patients were
treated with ICIs including PD-1 inhibitors, and 3.5% of the patients developed
interstitial lung diseases (ILDs)22. Fortunately, grade 3 or higher pulmonary adverse
events are relatively uncommon in patients.
The underlying etiology and mechanisms of pneumonitis associated with
anti-PD-1/PD-L1 mAbs have not been completely determined. One of the potential
risk factors for developing irAEs is due to pre-existing autoimmune diseases or
subclinical autoimmune syndromes. The PD-1/PD-L1 signaling pathway is an
evolutionarily conserved mechanism that maintains self-tolerance mainly through the

inhibition of self-reactive T/B cell responses23. Autoimmune conditions can be
exacerbated by lowering the threshold for immune activation through checkpoint
inhibition24, resulting in significantly increased risk of irAEs without affecting the
therapeutic effects25. Another possible mechanism for immune-related pulmonary
toxicity is elicited against antigens shared by the tumor and irAE lesions. It has been
suggested that pneumonitis observed in patients under PD-1 blockade may be related
to the T cells that are similar to the tumor-infiltrating T cells. Moreover, involved T
cell clones were also found in the peripheral blood26, which means any organ with
alike antigens may be inflicted by the circulating antigen-specific T cells.
Interestingly, anti-PD-1 mAbs have been associated with a slightly higher incidence
of pneumonitis as compared to anti-PD-L1 mAbs (3.6% vs. 1.3%), especially
regarding to the grade 3–4 pneumonitis (1.1% vs. 0.4%)20. A meta-analysis estimated
that the incidence of any grade pneumonitis among NSCLC patients on anti-PD-1
therapies is 4.1%18. One of the possible mechanisms for higher incidence of
PD-1-induced pneumonitis lies in the prevention of interaction between PD-L2 and
PD-1 by PD-1 blockade. The PD-L2 ligand mainly expresses on DCs, macrophages,
Th2 cells and activated T cells. On one hand, Latchman et al. identified that both
PD-1-PD-L2 and PD-1-PD-L1 signals inhibited the cytokine production and/or cell
proliferation of CD4+ T cells by blocking cell cycle progression27. On the other hand,
PD-1 blockade increases the binding of PD-L2 to repulsive guidance molecule b
(RGMb) that expresses in various cancer lines, mouse splenic CD4+ and CD8+ T
cells, pulmonary interstitial macrophages, and alveolar epithelial cells, thus leading to
vigorous clonal expansion of lung resident T cells and subsequent pneumonitis in the
absence of PD-1-mediated tolerance to self-antigens28. In addition, a recent study
provides evidence of direct interactions between tumor stroma and T cells, showing
that reciprocal expression of ligands FASL and PD-L2 was detected in
cancer-associated fibroblasts that kill CD8+ T cell via the interaction of PD-L2 with
PD-1 and FASL with FAS29. Therefore, the absence of interplay between PD-1 and
PD-L2 not only promotes the cytokine production and expansion of self-reactive T
cells, but also exempts them from being braked and eliminated, which may sharply
enhance the anticancer effect as well as the side effects. While PD-L1 blockade could,
to an extent, circumvent the restrictions above. This may partially explain the
incidence disparity of pulmonary toxicity between PD-1 and PD-L1 blocking30.
Anti-PD-1/PD-L1 therapy-related pneumonitis can manifest as shortness of breath,
cough, fever, or chest pain19. Standard of care is guided by clinical symptoms,
recommending that mild cases (grade 1–2) are managed with suspending therapy, and
higher grade cases with oral or intravenous corticosteroids (grade 2–4), among which
severe cases result in hospitalization for intravenous corticosteroids, the permanent
cessation of ICIs, and other forms of immunosuppression such as infliximab31.

Pulmonary toxicity in TRT
Delivery of ionizing radiation to thoracic region in cancer patients, particularly in
NSCLC patients, faces a major limitation known as the radiation-induced lung
injuries (RILIs), which is thought to be caused by reactive oxygen species produced
during the treatment course that leads to DNA damage and subsequent inflammatory
responses32. Radiation pneumonitis, usually occurring 1–6 months after RT, and
pulmonary fibrosis, developing gradually months to years later, are recognized as the
acute and late phases in the development of RILI, respectively33. Symptoms relevant
to RILI are often observed 1–6 months after RT, and may manifest as dyspnea, cough,
pyrexia, and mild chest pain. On symptoms progressing, acute respiratory distress
inflicted on patients can be life-threatening. RILI is commonly managed with
glucocorticoids, supplemental oxygen, as well as antitussive medications if clinically
indicated32.
The primary and optimal strategy to prevent RILI is through rigorous radiation
treatment planning to reduce the development of RILI. Treatment plans are generally
designed to achieve the percent of total lung volume receiving 20 Gy (V20) ≤ 30-37%
and mean lung dose of ≤ 20-21 Gy33. Still, RILI cannot be avoided completely even
with high-precision TRT. Delineation of clinical target volume and planning target
volume requires margins around the tumor in consideration of microscopic diseases,
respiratory motion, and setup variability. These margins increase the exposure of
benign tissues to high-dose radiation and stimulate an inflammatory and immune
reaction34.
More importantly, disease progression poses a more serious risk than adverse events
in patients receiving concurrent chemoradiotherapy. Therefore, adequate therapeutic
tumor dose coverage is paramount, and some benign lung tissue will receive TRT for
treating lung cancer. Taking the clinical trial RTOG 0617 as an example, a
randomized phase III trial of concurrent chemoradiotherapy comparing 74 vs. 60 Gy
and the use of chemoradiation with or without the addition of cetuximab, reported that
without cetuximab the rate of grade ≥ 3 acute pneumonitis was about 5% with 60 Gy
and less than 1% with 74 Gy (P = .25), while grade ≥ 3 late pulmonary toxicities
(pneumonitis and pulmonary fibrosis) was around 2% in both groups35. The secondary
analysis of RTOG 0617 comparing intensity-modulated radiation therapy (IMRT)
with three-dimensional conformal external beam radiation therapy (3D-CRT) found
that IMRT was less likely to induce severe pneumonitis (grade 3 pneumonitis, 3.5%
vs. 7.9%, P = .039) and improved quality of life36.
Other factors also known to influence the risk of pneumonitis development include
smoking history, preexisting pulmonary function, tumor size and location, heart
irradiation dose, select cytokine and glycoprotein levels, the receipt of carboplatin
plus paclitaxel chemotherapy in addition to V20, and advanced age33,37. Among them,
biomarkers, like IL-1α, IL-6, IL-8, sICAM-1, KL-6, CYFRA 21-1, TGF-β1, IP-10,
MCP-1 and TIMP-1, are implicated to correlate with higher-grade pulmonary

toxicity33,38,39. As an example, TGF-β1, which is activated by RT, facilitates the
development and persistence of tissue remodeling and fibrosis in response to
irradiation (Figure 1B and 1C). Notably, the production of TGF-β1 by
tumor-associated regulatory T cells also has an important role in preventing the
development of autoimmunity, which suppresses effector T cells and stimulate the
immunosuppressive function of myeloid-derived suppressor cells40,41.
Pulmonary toxicity with combined radiation and immunotherapy in the
pre-clinical and clinical settings
Pre-clinical data
So far, most studies combining ICIs and TRT have suggested an acceptable safety
profile in the oligometastatic cancer setting17. However, this data lacks robust
randomized data. We speculate that the pulmonary toxicity would be increased as
compared to a single modality, since the therapies may induce pulmonary toxicity
together and could compromise this otherwise promising combination therapy. Briefly,
TRT generates oxidative damage to DNA and proteins in lung tissue, causing
pulmonary injuries and contributing to the release of tumor antigens and
inflammatory factors. After tumor-antigen uptake and processing, antigen-presenting
cells migrate to lymphoid organs, and activate naïve T cells therein to become effector
T cells. Activated T cells that are further unleashed by anti-PD-1/PD-L1 therapy not
only maintain powerful killing effect that may impair normal self-tissues, but can also
secrete high-level cytokines that recruit more, even redundant immunocytes into the
local regions of the lung. While immunosuppression mechanisms that include
myeloid-derived suppressor cells and regulatory T cells are compromised in this
setting. Thus, the synergistic interaction of the two treatments sharply amplifies
anti-tumor effects, which may also exacerbate the pulmonary toxicity9,34. All of these
events could magnify serious adverse effects relevant to DNA damage, redundant
immunocytes infiltrating and inflammatory factors release, as well as collagen
deposition, which goes against the theory of immune normalization that emphasizes
the importance of recovering the lost antitumor immunity rather than immune
enhancement2. (Figure 1C).
Multiple pre-clinical studies have contributed to uncovering the mechanisms
underlying the synergistic effect. To name a few examples, tumor antigen-specific
interferon-γ produced by effector T cells was substantially enhanced locally by PD-1
blockade in the presence of RT41. Remaining to be one of the most important
pro-inflammatory cytokines, interferon-γ overexpression is also associated with a
number of auto-inflammatory and autoimmune diseases42, which is reminiscent of the
possible mechanisms of irAEs induced by anti-PD-1/PD-L1 therapy that is mentioned
above. More specifically, Deng et al. demonstrated that combination therapy with IR
and PD-L1 blockade optimizes antitumor immunity through enhanced production of T
cell-derived tumor necrosis factor (TNF)9. TNF-α has been implicated in the
pathogenesis of RILI and the induction of TGF-β138. Further, the elevation of plasma

TGF-β1 during radiation therapy predicts radiation-induced pulmonary toxicity,
which have been demonstrated in our pre-clinical study43. Of note, we also suggested
that concurrent anti-PD-1 therapy during TRT could augment pulmonary toxicity and
the consequent mortality in the mouse model, where CD8+ T lymphocytes and
macrophages with strong positivity for TGF-β1 may have played a key role during the
pathological process11. Therefore, the upregulation of TNF and TGF-β1 may partially
account for the pulmonary toxicity of the combination therapy.
Lastly, a recent perspective by Eric D. and Joe Y. Chang proposed that irradiation of
each lesion within multiple tissue beds would fully expose both mutual and exclusive
tumor-associated antigens and increase the probability of systemic activation of
antitumor immunity better than ICI monotherapy. However, they warned that the
safety of multisite comprehensive irradiation has not been routinely analyzed,
concerns regarding the toxicities of this approach still remain44.
Clinical data
Radiotherapy has been thought to be the ideal partner for ICIs44. Although there have
been several prospective clinical trials combining RT and PD-1/PD-L1 inhibitors
(Table 1) started in recent years, most of the trials are still ongoing. Only a small
amount of evidence for this combination therapy is available for us at the present
moment, and the safety profile appears to be acceptable (Table 2).
Some case reports suggest caution for the diagnosis and management of the toxicity
from the combination therapy. Louvel et al. reported two cases of six patients treated
with concomitant therapy of PD-1/PD-L1 inhibitors and SBRT who developed a
radiation pneumonitis45. Manapov et al. presented that 3 of 25 patients with advanced
NSCLC received nivolumab that was initiated as second or third-line therapy several
months after TRT developed grade 3 pneumonitis46. Yet it was uncertain whether
these cases were just related to TRT or if the combination with ICIs played any
enhancing role. More interestingly, Shibaki et al. presented two cases of
nivolumab-induced radiation recall pneumonitis, where two patients with NSCLC
received nivolumab treatment 2 years after 60 Gy of TRT developed pneumonitis.
The area of nivolumab-induced pneumonitis was consistent with the radiation field in
both patients47. Although the mechanism of recall pneumonitis is unknown, it seems
presumable that nivolumab may have evoked an inflammatory reaction in the
patients` previously irradiated fields.

Registration
Number

Phases

Tumor
Stage

NCT03446547

Ⅱ

Ⅰ

NCT03383302

Ⅰ/Ⅱ

NCT02768558

Intervention / Treatment

Arms

Durvalumab 1500 mg i.v. every fourth week following SBRTa.

SBRT vs. SBRT + Durvalumab

Ⅰ/Ⅱ

A flat dose of 240 mg nivolumab infusion will begin after the final fraction
of SBRT within 24 hours and subsequently be given every 2 weeks at a flat
dose of 240 mg.

SBRT + Nivolumab (adjuvant)

Ⅲ

Ⅲ

Patients will receive 60 Gy of thoracic RT; Cisplatin and Etoposide
followed by Nivolumab/Placebo 2 weeks.

Placebo vs. CRTb + Nivolumab

NCT03245177

Ⅰ

Ⅲ, Ⅳ

The first dose of pembrolizumab is administered 14 days prior to the
initiation of radiotherapy (60-66 Gy in 2 Gy/f, over 40-45 days) and
following radiotherapy every 3 weeks thereafter.

RTc + Pembrolizumab (concurrent)

NCT02434081

Ⅱ

Ⅲ A/B

Four doses of nivolumab 360 mg concurrently with standard
chemo-radiotherapy, followed by 480mg from start of nivolumab treatment.

CRT + Nivolumab
(concurrent & adjuvant)

NCT03368222

Ⅰ

Ⅲ B/ Ⅳ

Part A-DOSE LEVEL 1: 200 mg pembrolizumab in week 1 (then 3 weekly)
+ SBRT dosed at 30 Gy in 3 fractions in week 3. DOSE LEVEL 2: 200 mg
pembrolizumab in week 1 (then 3 weekly) + SBRT at 54Gy/ 3f in week 3.

RT + Pembrolizumab
(concurrent & adjuvant)

Part B-12 patients receive 200 mg of pembrolizumab in week 1 (then 3
weekly) + SBRT in week 3.
NCT02621398

Ⅰ

Ⅱ–Ⅲ B

Beginning 2–6 weeks after, 2 weeks before the end, or at the start of
chemotherapy and radiation therapy, patients also receive pembrolizumab.

CRT + Pembrolizumab (concurrent)

NCT03307759

Ⅰ

IV

SABRd followed by pembrolizumab vs. Pembrolizumab followed by SABR
after cycle 1

SABR + Pembrolizumab
(concurrent vs. adjuvant)

NCT03158883

Ⅰ

IV

Avelumab: 10 mg/kg administered q2w.

SABR + Avelumab
(concurrent & adjuvant)

SABR: 50 Gy/5f on every 2 day
NCT03044626

Ⅱ

Ⅳ

Nivolumab 240 mg fixed dose (q2w). First dose followed by radiotherapy.
A metastatic site will be treated with a radiation dose at 20 Gy/5f during a
two-week time interval.

SBRT + Nivolumab
(concurrent & adjuvant)

NCT02407171

Ⅰ/Ⅱ

IV

The starting radiotherapy dose will be 30 Gy/5f and a dose escalation cohort
(30Gy/ 3f). MK-3475: 200mg every 2 weeks

SBRT + MK-3475
(concurrent & adjuvant)

NCT02400814

Ⅰ

IV

Concurrent: MPDL3280A on day 1; SABR begins on day 1 of course 1.

SABR + MPDL3280A
(concurrent vs. adjuvant vs.
sequential)

Induction: MPDL3280A on day 1; SABR begins on day 1 of course 3.
Sequential: SABR begins on day 1 of course 1. After completion of SABR,
MPDL3280A IV begins.

NCT03313804

Ⅱ

IV

Immune checkpoint inhibitor PLUS SBRT

SBRT + Nivolumab/Pembrolizumab
/Atezolizumab

NCT03212469

Ⅰ/Ⅱ

IV

Durvalumab q4w+ Tremelimumab q4w for up to 4 doses in conjunction
with SBRT, then Durvalumab q4w alone for up to 9 additional doses.

SBRT + Durvalumab +
Tremelimumab

NCT02444741

I/II

IV

PhaseⅠ: Starting dose of Pembrolizumab 100 mg by vein on Day 1 of each
3-week cycle.

Pembrolizumab + SBRT/ WFRT vs.
Pembrolizumab

PhaseⅡ: Starting dose of Pembrolizumab at the maximum tolerated dose
from Phase I. SBRT delivered at 50 Gy in 4 daily fractions. Wide-field
radiation therapy delivered at 45 Gy in 15 daily fractions.

Table 1. Ongoing clinical trials that are testing the effects of combinatorial therapy of programmed cell
death 1 (PD-1) /programmed cell death ligand 1 (PD-L1) inhibition and RT in the treatment of lung
cancer. SBRTa: Stereotactic body radiation therapy; CRTb: Chemoradiotherapy;
RTc: Conventional fractionated radiotherapy; SABRd: Stereotactic ablative radiotherapy.

Study

Study Type

Nishino M, et al.18

Meta-analysis.
(Including phase I–III)

Khunger M, et al.20

Meta-analysis.
(Including phase I–Ⅳ)

Bradley JD, et al. 35

Prospective study
(Phase III)

Tumor and Stage
Only NSCLCa included
in this table
NSCLC

Stage IIIA/IIIB NSCLC

Intervention / Treatment
PD-1b inhibitor monotherapy

Incidences of Pulmonary Toxicities

All-grade pneumonitis: 4.1%

PD-1/PD-L1c inhibitor
monotherapy

All-grade pneumonitis: 3.6% in PD-1
inhibitors, 1.3% in PD-L1 inhibitors

TRTd: 60 Gy vs. 74 Gy
(without chemotherapy)

All-grade acute pneumonitis: about
9% in the 60 Gy arm, about 11% in
the 74 Gy arm
All-grade late pneumonitis: about
12% in the 60 Gy arm, 7% in the 74
Gy arm
All-grade late pulmonary fibrosis:
10% in the 60 Gy arm, 6% in the 74
Gy arm

Curran WJ, et al. 48

Antonia SJ, et al.12

Prospective study
(Phase III)

Prospective study
(Phase III)

Stage II, IIIA, or IIIB

Chemotherapy + TRT:
Arm 1: sequential (63 Gy)
Arm 2: concurrent (63 Gy)
Arm 3: concurrent (69.6 Gy)

Locally advanced NSCC

CRTe + Durvalumab

Grade ≥ 3 acute pulmonary toxicities:
9% in arm 1, 3-4% in arm 2 and 3;
Grade ≥ 3 late pulmonary toxicities:
14% in arm 1, 13% in arm 2 and 17%
in arm 3;

All-grade pneumonitis: 33.9%
All-grade pneumonia: 13.1%
Grade ≥ 3 pneumonitis: 3.4%
Grade ≥ 3 pneumonia: 4.4%

Shaverdian, N, et al.13

Post hoc analysis

Advanced NSCC

TRT + Pembrolizumab

All-grade pulmonary toxicities: 13%

Peters S, et al.49

Prospective study
(Phase II)

Stage III NSCLC

CRT + Nivolumab

All-grade pneumonitis: 35.4%

Prospective study
(Phase II)

Stage III NSCLC

Retrospective study

NSCLC

Durm, G. A., et al.50

Botticella, A., et al.51

All-grade Pulmonary fibrosis: 1.7%
CRT + Pembrolizumab

Grade ≥ 2 pneumonitis: 17.2%
Grade ≥ 3 pneumonitis: 6.5%

TRT+ICIsf

All-grade pneumonitis: 16.7%
Grade ≥ 3 pneumonitis: 11.1%

Reibnitz, D, et al.

52

Retrospective study

Advanced lung cancer
or other tumors with lung
metastases

TRT + anti-PD-1/PD-L1 (78%) /

Grade ≥ 2 pneumonitis: 6.3%

anti-CTLA-4 (15%) /

Grade ≥ 2 pneumonia: 17.7%

anti-PD-1/PD-L1 and
anti-CTLA-4 (6%)

Hwang WL, et al.17

Retrospective study

Metastatic NSCLC (95%)
and SCLCg (5%)

TRT + anti-PD-1/PD-L1

All-grade pneumonitis: 8.2%

Voong KR, et al.53

Retrospective study

NSCLC

TRT + anti-PD-1/PD-L1

All-grade pneumonitis: 25%

Shibaki R, et al.47

Case report

NSCLC

TRT + Nivolumab

Two patients with nivolumab-induced
radiation recall pneumonitis

Manapov F, et al.46

Case report

Advanced NSCLC

TRT + Nivolumab

Three patients with grade 3
pneumonitis

Louvel G, et al.45

Case report

Patient 1: metastatic
melanoma

Patient 1: concomitant
pembrolizumab + TRT

Two patients with radiation
pneumonitis

Patient 2: metastatic
colon cancer

Patient 2: concomitant
atezolizumab + TRT

Table 2. Important studies reporting pulmonary toxicity of monotherapy and of the combination of
thoracic radiotherapy (TRT) and programmed cell death 1/programmed cell death ligand 1 inhibition.
Pneumonitis and pneumonia are both included in the pulmonary toxicity analysis, because differential

diagnosis between pneumonia and pneumonitis relating to immunotherapy or radiotherapy may be
clinically challenging. NSCLCa: Non-small cell lung cancer; PD-1b: programmed cell death 1; PD-L1c:
programmed cell death ligand 1; TRTd: Thoracic radiotherapy; CRTe: Chemoradiotherapy; ICIsf:
immune checkpoint inhibitors; SCLCg: Small cell lung cancer

As for retrospective studies, most of them appear to claim that combining PD-1
inhibitors and RT does not result in increased toxicity. Bang et al. retrospectively
reviewed patients with metastatic NSCLC, melanoma and renal cell cancer, who
received CTLA-4 or PD-1 inhibitors and palliative radiotherapy. No relationship
between radiation fields and specific irAEs was identified. For instance, 2 in 34
patients (6%) who received TRT and 1 of 79 patients (1%) who did not developed
pneumonitis (P = .16)54. A retrospective cohort study by Hwang et al. included
patients with metastatic lung cancer treated with anti-PD-1/PD-L1 therapy. Incidences
of all-grade pneumonitis (8.2% vs. 5.5%) as well as pneumonitis grade ≥ 2 (4.1% vs.
3.3%) were not significantly different between the TRT and non-TRT cohorts17.
Naidoo et al. analyzed patients who received anti-PD-1/PD-L1 mAbs monotherapy or
in combination with anti-CTLA-4 mAb, and revealed that most of the patients that
developed pneumonitis had not received prior TRT (27 of 43 [63%])55.
In stark contrast, one study group from Johns Hopkins University retrospectively
investigated the role of TRT and the development of immune-related pneumonitis in
184 NSCLC patients who received anti-PD-1/PD-L1 therapy. Anti-PD-1/PD-L1
monotherapy was received in 74% and in combination with other systemic therapy in
26% of the patients. TRT was performed 96 patients (52%). A total of 38 (21%)
patients developed pneumonitis, which was more common than that were reported in
other clinical trials. Moreover, there was a strong trend towards increased
immune-related pneumonitis in patients who underwent TRT compared with those
who received other RT (25% vs. 9%, P = 0.08)53. Together with another retrospective
study by the same study group, the overall incidence of checkpoint inhibitor
pneumonitis is found to be significantly higher than that was reported in other clinical
studies56. The retrospective study by Botticella et al. also supported that NSCLC
patients treated with ICIs and previous curative-intent TRT may be at higher
pulmonary risk, where pneumonitis of grade ≥ 3 occurred in 16.7% of the patients on
combination therapy and in 2.4% of the patients on ICI monotherapy (P < 0.001)51.
Possible reasons include increased awareness and pharmacovigilance with irAEs in
recent years.
However, limitations of the above retrospective analyses are inherent to the nature of
such studies, including incomplete information, lengthy median time between TRT
and ICI treatment, and combined analysis of different doses and purposes. Therefore,
we should be careful when extrapolating this information.
In the post hoc analysis of the phase I KEYNOTE-001 trial (NCT01295827), all
included patients with advanced NSCLC received pembrolizumab and were coded for

having received previous RT (extracranial or thoracic) or not. Significantly prolonged
PFS and OS were observed in patients with advanced NSCLC who had received any
RT before receiving pembrolizumab than that in patients who did not have. Of note,
comparing the 24 patients who received previous TRT and the 73 patients who did not,
there was a statistical increase in treatment-related pulmonary toxicities (13% vs. 1%,
P = .046), and a borderline significance was found in the incidence of all pulmonary
toxicities (63% vs. 40%, P = .052), including dyspnea, cough, pneumonitis, and
respiratory failure. Although no frequency difference was found in the grade ≥ 3
pulmonary toxicity in both treatment-related pulmonary toxicities and all pulmonary
toxicities, RT was implemented at a median of 11.5 months before pembrolizumab
treatment13. Exposing NSCLC patients to TRT can induce RILI that develop over
weeks to months or years33. In this study, since TRT was performed several months
(median 9.5 months, range 1.0-106.0) prior to ICIs, patients with RILI, especially
with severe pneumonitis (grade ≥ 3), may well be excluded from the subsequent ICIs
therapy as per the exclusion criteria of most clinical trials. That is, those who received
combination therapy were pulmonary function-competent and more likely to
withstand the subsequent immunotherapy. In conclusion, KEYNOTE-001 trial can, to
some extent, support our perspective that combination therapy augments pulmonary
toxicities.
The PACIFIC study (NCT02125461), a prospective, randomized, double-blind,
placebo-controlled phase III study enrolled patients with locally advanced NSCLC
that had received platinum-based chemotherapy concurrently with definitive radiation
therapy (54–66 Gy). Durvalumab, a PD-L1 inhibitor, was administered 1 to 42 days
after completion of chemoradiotherapy in the experimental arm, while placebo was
administered in the control arm. Pneumonitis of any grade occurred in 33.9% and
24.8% of patients in the durvalumab arm and placebo arm, respectively; grade 3 and 4
occurred in 3.4% and 2.6%, respectively12. P-values for the pulmonary safety data
were not reported. The incidence of grade ≥ 3 pneumonitis in the placebo group was
comparable to that in RTOG 9410 (3.4% vs. 1–5%)35. However, pneumonitis of any
grade was more common in both treatment of PACIFIC than that in ATLANTIC
study, a durvalumab monotherapy study (33.9% & 24.8% vs. ≤ 3%)57. This variability
may be attributed to the requirement for prior TRT in PACIFIC, which could have
predisposed patients to pulmonary adverse events, a hint for the role of TRT in
increasing pulmonary side effects58. Symptoms such as cough (35.4% vs. 25.2%),
dyspnea (22.3% vs. 23.9%) and pyrexia (14.7% vs. 9.0%), which are possibly relevant
to RILI and have been included in KEYNOTE-001 trial and other studies19, were not
included in the pulmonary toxicity analysis of this study. Additionally, differentiating
between pulmonary infection (pneumonia in both arms: 13.1% vs. 7.7%) and
pneumonitis relating to immunotherapy or radiotherapy may be clinically
challenging59,60. Hence, we conjecture that the authentic incidence of pulmonary
toxicity has been underrated because of the exclusion of other respiratory symptoms
and pneumonia from pulmonary toxicity analysis.

Another multicenter single-arm phase II study spearheaded by Indiana University
adopting the same treatment mode as the PACIFIC study reported the incidence of
grade ≥ 3 pneumonitis at 6.5%, which is the double of the PACIFIC study50. However,
only 43.5% of patients completed the one-year adjuvant immunotherapy and 19.6%
failed due to adverse events, suggesting the incomplete information of pneumonitis
incidence on combination therapy. Of note, 75% cases of grade ≥2 pneumonitis
occurred within the first 12 weeks after pembrolizumab treatment50. Similarly, with
TRT and immunotherapy being prescribed sequentially rather than concurrently, the
report of the second primary endpoint for PACIFIC study revealed that time < 14 days
from prior RT to randomization witnessed quite different proportions of any-grade
pneumonitis (39.2% vs. 16.7%, without the P-value reported) in the durvalumab arm
and placebo arm61.which is reminiscent of concurrent combination therapy that is
more likely to prime a stronger immune response44 as well as worsen the pulmonary
toxicity in the light of published preclinical evidence from concurrent irradiation and
PD-1 blockade in increasing cardiac toxicity62,63. The safety data from NICOLAS
(NCT02434081) study, to some extent, corroborates our speculation. This is a
single-arm study evaluating the safety of combining nivolumab with the first-line
chemo-TRT (≥ 60 Gy) regimen in stage III NSCLC. Pneumonitis of any grade
occurred in 32.7% of the evaluated 58 patients, with grade 1/2 and 3 making up
22.4% and 10.3%, respectively. Pneumonitis of grade ≥ 3 is remarkably increased as
compared to studies above, while the remaining respiratory disorders, including
dyspnea (20.7%), cough (31.0%), pulmonary fibrosis (1.7%) and respiratory
insufficiency (1.7%), are comparable to other studies49.
Real-World Toxicities Higher Than in Trials
Even if prospective clinical trials, such as the PACIFIC study, have offered more
objective and reliable evidence as compared with retrospective studies, their results
may still not reflect the real-world data. For instance, patients with history of
interstitial lung disease (ILD) were routinely excluded from the clinical trials studying
the combination of ICIs and TRT. In fact, the incidence of lung cancer is high in
patients with idiopathic pulmonary fibrosis (25.2 cases per 1000 person-years), a
specific form of ILD of unknown cause64. NSCLC patients who were treated with
SBRT, the cumulative incidences of radiation pneumonitis worse than grade 2 (55.0%
vs.13.3%, P < .001) and worse than grade 3 were significantly higher in ILD (+)
group than those in ILD (−) group (10.0% vs. 1.5%; P = .02)65. Furthermore, referring
to the instructions of anti-PD-1/PD-L1 mAbs, in the case of grade 2 or higher-grade
immune-mediated pneumonitis or ILD, withholding immunotherapy is emphasized.
Collectively, patients with ILD are more prone to pulmonary toxicities by TRT, ICIs,
or more possibly by the combination therapy. The exclusion of this patient group
could artificially reduce the incidence of combination therapy-related pneumonitis.
Additionally, with the improvement of medical technology and our ability to diagnose
irAEs, rates are increasing as observed at the population level56.

Conclusion
Since most irAEs are treatable, recognizing these events earlier on could improve
quality of life of patients. Our purpose is to promote awareness amongst medical
oncologists, radiation oncologists, pulmonologists, emergency physicians, and other
medical providers to have a high index of suspicion of potential pulmonary toxicity
from the combination of radiation therapy with immunotherapy in the setting of
advanced NSCLC. Most of the available data suggests that combining radiation and
immune checkpoint blockade are generally safe, but more data with longer and rigorous
follow-up are needed. Whether such a treatment course is appropriate for patients
without risking undue toxicity from co-administration is left unanswered at this time.
The information presented above presents a potential trend towards increased
incidence of immune-related, radiation pneumonitis in patients on combination
therapy. Therefore, we are cautiously optimistic and recommend attention to
monitoring for pneumonitis in patients with NSCLC during combination therapy,
particularly with anti-PD-1/PD-L1 inhibitors.
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